Karyopharm Therapeutics Inc. — Q3 2014 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2014. Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions unless noted.
Business context
Karyopharm is a clinical-stage pharmaceutical company developing SINE compounds that inhibit XPO1. Its lead candidate, oral selinexor (KPT-330), was being studied in hematologic and solid-tumor indications. The company reported treating more than 450 patients in Phase 1 and Phase 2 trials. It had no revenue from drug sales; reported revenue was limited to contract and grant funding.
Financial results and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Contract and grant revenue | $0.021m | None | $0.214m | $0.366m |
| Research and development expense | $15.951m | $7.738m | $40.089m | $18.763m |
| General and administrative expense | $3.814m | $1.583m | $10.028m | $3.405m |
| Net loss | $(19.724)m | $(9.321)m | $(49.849)m | $(21.801)m |
| Net loss per share | $(0.61) | $(3.66) | $(1.63) | $(9.11) |
- At September 30, cash and cash equivalents were $227.1m, versus $156.0m at December 31, 2013; restricted cash was $0.4m. Current assets were $231.3m and current liabilities $6.2m.
- Cash used in operating activities for the first nine months was $38.7m, compared with $20.2m a year earlier. Investing activities used $3.1m; financing provided $113.0m, primarily from a July common-stock offering that raised approximately $112.8m net.
- Total liabilities were $7.4m. The filing reports no debt balance. No profit or meaningful operating margin was reported; losses reflected the company’s development-stage operations.
- Accumulated deficit was $112.4m. Stock-based compensation expense was $9.6m for the first nine months.
Material changes and management commentary
- Q3 R&D expense more than doubled year over year, driven mainly by higher clinical-trial and selinexor manufacturing costs, personnel and stock compensation, preclinical studies, and occupancy. Nine-month R&D expense rose by $21.3m.
- Q3 G&A expense increased by about $2.3m year over year; the nine-month increase was about $6.6m. Higher staffing, stock-based compensation, consulting, professional fees, and public-company costs were principal factors.
- Nine-month contract and grant revenue declined to $0.214m from $0.366m. The company stated that it recognized less grant funding.
- The July 2014 offering sold 2,844,334 shares at $42.50 per share, including the underwriters’ option; net proceeds were approximately $112.8m. Common shares outstanding were 32,614,387 at quarter-end.
- Management expected expenses and operating losses to increase as research and clinical development continued. It estimated that existing cash would fund its current operating plan and capital expenditure needs into the second half of 2017, and expected to end 2014 with more than $200m in cash and cash equivalents.
Outlook, risks and unusual items
- The company had initiated a registration-directed trial in older patients with acute myeloid leukemia in June 2014. Management planned a registration-directed DLBCL trial in 2014 and up to two further trials in the first half of 2015, potentially including multiple myeloma. The filing also notes that a Richter’s Transformation trial began in November 2014, after quarter-end.
- Management said additional funding would be needed to achieve its longer-term objectives. If capital were unavailable on acceptable terms, the company might have to delay, reduce, or eliminate development or commercialization efforts. Runway estimates depend on trial progress and costs, regulatory outcomes, collaborations, and other funding needs.
- Key risks include clinical results not predicting later-trial success, failure to obtain regulatory approval or commercialize candidates, dependence on third parties, competition, intellectual-property protection, and the need for additional capital. Management cautioned that actual results may differ materially from forward-looking statements.
- The company entered a lease for approximately 29,933 square feet of office and research space, expiring in October 2021, with aggregate rent payments of approximately $5.6m; it also recorded a $0.4m lease-related restricted-cash deposit.
- Management recorded $1.1m of Q3 stock-compensation expense related to consultant awards, including an option vesting acceleration. The filing reported no legal proceedings, material changes to contractual obligations during the quarter, or off-balance-sheet arrangements.
Important facts for investors to verify
- Whether clinical-trial progress and results support the planned registration-directed programs and their timelines.
- Whether actual cash burn remains consistent with management’s projected runway into the second half of 2017, particularly as trial spending expands.
- The sustainability and composition of rising R&D, personnel, consulting, and stock-based compensation costs.
- Future financing needs, potential dilution, and the company’s ability to secure funding on acceptable terms.
- Trial, regulatory, manufacturing, collaboration, and intellectual-property risks highlighted in the filing and subsequent reports.